Briumvi Now Available for Multiple Sclerosis Treatment
The CD20-directed cytolytic antibody therapy was approved based on data from two phase 3 trials.
Diagnosis & Disease Information
Briumvi Approved for Relapsing Forms of Multiple Sclerosis
The approval was based on data from the phase 3 ULTIMATE 1 and ULTIMATE 2 trials that compared ublituximab-xiiy to teriflunomide in patients with relapsing multiple sclerosis.
Autologous Hematopoietic Stem Cell Transplant Slows Disability Progression in MS
Slowing of disability progression and higher likelihood of disability improvement observed compared with standard disease-modifying therapies
Treatments Compared for Pediatric-Onset Multiple Sclerosis
More pediatric patients free of new or newly enlarging T2 lesions at week 96 with dimethyl fumarate versus interferon beta-1a
Ublituximab Bests Teriflunomide in Relapsing Multiple Sclerosis
About 48 percent of participants receiving ublituximab had infusion-related reactions
Medication Error Possible if Incompatible Autoinjector Used to Administer MS Drug
Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis.
Natalizumab Biosimilar to Get FDA Review for MS, Crohn Disease Indications
The application is under review for relapsing forms of multiple sclerosis and Crohn disease.
June 2022 Recap: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
COVID-19 Linked to Increased Risk of Neurological Disorders
Most neurological disorders do not appear to be more frequent after COVID-19 than after influenza or bacterial pneumonia
